RT Journal Article
SR Electronic
T1 Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.01.21250959
DO 10.1101/2021.02.01.21250959
A1 Davies, Nicholas G.
A1 Jarvis, Christopher I.
A1 ,
A1 Edmunds, W. John
A1 Jewell, Nicholas P.
A1 Diaz-Ordaz, Karla
A1 Keogh, Ruth H.
YR 2021
UL http://medrxiv.org/content/early/2021/02/11/2021.02.01.21250959.abstract
AB VOC 202012/01, a SARS-CoV-2 variant first detected in the United Kingdom in September 2020, has spread to multiple countries worldwide. Several studies have established that this novel variant is more transmissible than preexisting variants, but have not identified whether it leads to any change in disease severity. We analyse a large database of SARS-CoV-2 community test results and COVID-19 deaths, representing 52% of all SARS-CoV-2 community tests in England from 1 September 2020 to 5 February 2021. This subset of SARS-CoV-2 tests can identify VOC 202012/01 because mutations in this lineage prevent PCR amplification of the spike gene target (S gene target failure, SGTF). We estimate that the hazard of death among SGTF cases is 58% (95% CI 40–79%) higher than among non-SGTF cases after adjustment for age, sex, ethnicity, deprivation level, care home residence, local authority of residence and test date. This corresponds to the absolute risk of death for a male aged 55–69 increasing from 0.6% to 0.9% (95% CI 0.8–1.0%) over the 28 days following a positive test in the community. Correcting for misclassification of SGTF and missingness in SGTF status, we estimate a 71% (48–97%) higher hazard of death associated with VOC 202012/01. Our analysis suggests that VOC 202012/01 is not only more transmissible than preexisting SARS-CoV-2 variants but may also cause more severe illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding statement NGD: UK Research and Innovation (UKRI) Research England; NIHR Health Protection Research Unit in Immunisation (NIHR200929); UK Medical Research Council (MC_PC_19065). CIJ: Global Challenges Research Fund project 'RECAP' managed through Research Councils UK and the Economic and Social Research Council (ES/P010873/1). WJE: European Commission (EpiPose 101003688), National Institutes of Health Research (NIHR200908). NPJ: National Institutes of Health / National Institute of Allergy and Infectious Diseases (R01AI148127). KDO: Royal Society-Wellcome Trust Sir Henry Dale Fellowship 218554/Z/19/Z. RHK: UKRI Future Leaders Fellowship (MR/S017968/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by the Observational / Interventions Research Ethics Committee at the London School of Hygiene and Tropical Medicine (reference number 24020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysis code is available at https://github.com/nicholasdavies/cfrvoc. An anonymised data set allowing replication of the analysis is available at the same URL. https://github.com/nicholasdavies/cfrvoc